Matthew C. Kapusta Sells 26,727 Shares of uniQure (NASDAQ:QURE) Stock

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 26,727 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $285,978.90. Following the completion of the sale, the chief executive officer now directly owns 571,188 shares in the company, valued at $6,111,711.60. This represents a 4.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

uniQure Trading Up 8.9 %

Shares of NASDAQ QURE opened at $13.15 on Friday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The firm has a 50 day moving average price of $15.05 and a two-hundred day moving average price of $9.79. The stock has a market cap of $640.73 million, a P/E ratio of -2.65 and a beta of 0.38.

Institutional Investors Weigh In On uniQure

Large investors have recently modified their holdings of the company. RTW Investments LP acquired a new stake in shares of uniQure during the third quarter worth $49,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares in the last quarter. Atria Investments Inc bought a new position in shares of uniQure during the third quarter valued at about $53,000. Quarry LP bought a new position in shares of uniQure during the third quarter valued at about $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of uniQure during the third quarter valued at about $69,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

QURE has been the topic of several research reports. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $20.00 to $52.00 in a research report on Tuesday, December 10th. HC Wainwright boosted their price objective on shares of uniQure from $25.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Wells Fargo & Company lowered their price objective on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday. Cantor Fitzgerald increased their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. Finally, Stifel Nicolaus increased their price objective on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 16th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, uniQure has an average rating of “Moderate Buy” and an average target price of $38.89.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.